Αποτελέσματα Αναζήτησης
In late 2013, the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) approved a new set of diagnostic criteria for systemic sclerosis (SSc), replacing the older 1980 diagnostic criteria.
- Differential Diagnosis
Even though the old names are still being used, there are...
- Differential Diagnosis
The Scleroderma FAQ* is a comprehensive document that covers systemic scleroderma diagnosis and treatment. All information contained in the FAQ is based on current medical research and includes up-to-date information on new diagnostic criteria and treatments for systemic scleroderma.
3 Νοε 2023 · Initial symptoms are non-specific and include fatigue, vague musculoskeletal complaints, diffuse swelling of hands, and Raynaud's phenomenon. Aetiology and pathogenesis are unknown. Disease course is variable, but the condition rarely subsides spontaneously.
5 Απρ 2024 · Introduction. Systemic sclerosis, also known as scleroderma, is a rare connective tissue disorder with an unknown and complex pathogenesis. Scleroderma can be divided into 2 primary forms—localized scleroderma (including morphea, linear scleroderma, and scleroderma en coup de sabre) and systemic sclerosis.
M34-. A chronic disorder, possibly autoimmune, marked by excessive production of collagen which results in hardening and thickening of body tissues. The two types of systemic scleroderma, limited cutaneous and diffuse cutaneous are classified with focus on the extent of affected skin.
29 Σεπ 2023 · There’s no cure for scleroderma, but your healthcare provider will help you find a combination of treatments that manages your symptoms and minimizes how much they impact your daily routine. Which treatments you’ll need depends on where you’re experiencing symptoms and how severe they are.
Even though the old names are still being used, there are now separate diagnostic categories for diffuse scleroderma (M34.0) and limited scleroderma (M34.1). There is also a specific code for systemic scleroderma caused by known exposure to drugs or toxic chemicals (M34.2).
